Dr. Louisa Temme

Research group leader

Institute of Pharmaceutical and Medicinal Chemistry
Corrensstraße 48
48149 Münster
Germany

+49 (0)251-83-33838

ORCID: 0000-0003-3753-4973
Google Scholar

Since 04/2020	Research group leader at the Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Germany
09/2018 – 03/2020	Postdoctoral research associate, SGC-UNC, University of North Carolina at Chapel Hill, USA
01/2018 – 07/2018	Pharmaceutical and Medicinal Chemistry, University of Münster, Germany Fellow of Cells-in-Motion Cluster of Excellence, Münster
03/2016	Pharmaceutical Chemistry and Clinical Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Germany
11/2013 – 01/2018	Ph.D. student in the group of Prof. Dr. B. Wünsch, Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Germany Dissertation: Negativ allosterische Modulatoren des GluN1a/GluN2B-NMDA-Rezeptors: In silico Docking, Synthese und Entwicklung eines Testsystems zur Bestimmung der Zytoprotektion, 321 pages, Münster, 2017.
07/2014	License to practice pharmacy (Approbation)
10/2008 – 04/2013	Study of pharmacy, University of Münster, Germany

Awards and scholarships

2021	Erstklassig (program of the University of Münster for female research group leaders)
2018	Carl‐Wilhelm‐Scheele‐Preis of the German Pharmaceutical Society (DPhG) for outstanding Ph.D. thesis
2018	Cells-in-Motion (CiM) Cluster of Excellence Bridging Position Cells-in-Motion (CiM) Cluster of Excellence Travel Grant for Female
2016	Researchers allowed participation at the International Conference on Medicinal Chemistry in Manchester (UK) in 2016
2016	Cells-in-Motion (CiM) Cluster of Excellence Train-Gain program funded the lab visit in the working group of Prof. Sippl, University of Halle-Wittenberg in 2016

Research

My general research interests include theoretical and experimental approaches aiming at the accelerated development of novel, selective and therapeutically active small molecules. To facilitate this research, medicinal chemistry techniques are applied including computational methods, synthesis, and biological evaluation.

We have a keen interest in the application and development of fragment-based drug discovery approaches. Among the targets of interest are proteins involved in cancer and infection biology.

If you want to know more about our research or become a member of my team, you can directly contact me in person or via email.

Further information is available here: temmelab.com

Membership

Member of the German Pharmaceutical Society (DPhG)

Member of the German Chemical Society (GDCh)

Research training group “Chemical biology of ion channels (Chembion)”

Publications

1. Maurice Dellin, Ina Rohrbeck, Purva Asrani, Julian A. Schreiber, Nadine Ritter, Frank Glorius, Bernhard Wünsch, Thomas Budde, Louisa Temme, Timo Strünker, Birgit Stallmeyer, Frank Tüttelmann, Sven G. Meuth, Marc Spehr, Johann Matschke, Andrea Steinbicker, Christos Gatsogiannis, Raphael Stoll, Nathalie Strutz-Seebohm and Guiscard Seebohm. The second PI(3,5)P2 binding site in the S0 helix of KCNQ1 stabilizes PIP2-at the primary PI1 site with potential consequences on intermediate-to-open state transition. Biol. Chem. 2023, 404 (4), 241–254. https://doi.org/10.1515/hsz-2022-0247

2. Louisa Temme#, Tuomo Laitinen and Christopher R. M. Asquith#. PKN3: a target in cancer metastasis. Nat. Rev. Drug Discovery, 2022, 21, 704. https://doi.org/10.1038/d41573-022-00154-7, #shared first authorship

3. Christopher R. M. Asquith#, Louisa Temme#, Michael P. East, Tuomo Laitinen, Julie Pickett, Frank E. Kwarcinski, Parvathi Sinha, Carrow I. Wells, Gary L. Johnson, Reena Zutshi, and David H. Drewry. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype. ChemMedChem, 2022, e202200161. https://doi.org/10.1002/cmdc.202200161,#shared first authorship

4. Benjamin J. Eduful, Sean N. O’Byrne, Louisa Temme, Christopher R. M. Asquith, Yi Liang, Alfredo Picado, Joseph R. Pilotte, Mohammad Anwar Hossain, Carrow I. Wells, William J. Zuercher, Carolina M. C. Catta-Preta, Priscila Zonzini Ramos, André de S. Santiago, Rafael M. Couñago, Christopher G. Langendorf, Kévin Nay, Jonathan S. Oakhill, Thomas L. Pulliam, Chenchu Lin, Dominik Awad, Timothy M. Willson, Daniel E. Frigo, John W. Scott, and David H. Drewry. Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes. J. Med. Chem., 2021, 64, 10849–10877. https://doi.org/10.1021/acs.jmedchem.0c02274

5. Louisa Temme and Christopher R. M. Asquith, eEF2K: an atypical kinase target for cancer. Nat. Rev. Drug Discovery, 2021, 20, 577. https://doi.org/10.1038/d41573-021-00124-5

6. Christopher R. M. Asquith and Louisa Temme, STK19: a new target for NRAS-driven cancer. Nat. Rev. Drug Discovery, 2020, 19, 579. https://doi.org/10.1038/d41573-020-00116-x

7. Louisa Temme, Elena Bechthold, Julian A. Schreiber, Sandeep Gawaskar, Dirk Schepmann, Dina Robaa, Wolfgang Sippl, Guiscard Seebohm, Bernhard Wünsch. Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds. Eur. J. Med. Chem., 2020, 190, 112138. https://doi.org/10.1016/j.ejmech.2020.112138

8. Louisa Temme, Frederik Börgel, Dirk Schepmann, Dina Robaa, Wolfgang Sippl, Constantin Daniliuc, Bernhard Wünsch. Impact of hydroxy moieties at the benzo[7]annulene ring system of GluN2B ligands: Design, synthesis and biological evaluation. Bioorg. Med. Chem., 2019, 27, 115146. https://doi.org/10.1016/j.bmc.2019.115146

9. Louisa Temme, Bastian Frehland, Dirk Schepmann, Dina Robaa, Wolfgang Sippl, Bernhard Wünsch. Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation. Eur. J. Med. Chem., 2018, 144, 672–681. https://doi.org/10.1016/j.ejmech.2017.12.054

10. Louisa Temme, Dirk Schepmann, Julian A. Schreiber, Bastian Frehland, Bernhard Wünsch. Comparative pharmacological study of common NMDA receptor open channel blockers regarding their affinity and functional activity towards GluN1a/GluN2A- and GluN1a/GluN2B-NMDA receptors. ChemMedChem, 2018, 13, 446–452. https://doi.org/10.1002/cmdc.201700810

11. Frederik Börgel, Marina Szermerski, Julian A. Schreiber, Louisa Temme, Nathalie Strutz-Seebohm, Kirstin Lehmkuhl, Dirk Schepmann, Simon M. Ametamey, Guiscard Seebohm, Thomas J. Schmidt, Bernhard Wünsch. Synthesis and pharmacological evaluation of enantiomerically pure GluN2B selective NMDA receptor antagonists. ChemMedChem, 2018, 13, 1580-1587. https://doi.org/10.1002/cmdc.201800214

12. Ahmed Haider, Adrienne Müller Herde, Stefanie D. Krämer, Jasmine Varisco, Claudia Keller, Katrin Frauenknecht, Yves P. Auberson, Louisa Temme, Dina Robaa, Wolfgang Sippl, Roger Schibli, Bernhard Wünsch, Linjing Mu, Simon M. Ametamey. Preclinical Evaluation of Benzazepine-Based PET Radioligands (R)- and (S)-11C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and σ1-Receptor-Targeted PET Imaging. J. Nucl. Med., 2019, 60, 1167-1173. https://doi.org/10.2967/jnumed.118.221051

13. Sandeep Gawaskar, Louisa Temme, Julian A. Schreiber, Dirk Schepmann, Alessandro Bonifazi, Dina Robaa, Wolfgang Sippl, Nathalie Strutz-Seebohm, Guiscard Seebohm, Bernhard Wünsch. Design, synthesis, pharmacological evaluation and docking studies of GluN2B-selective NMDA receptor antagonists with a benzo[7]annulen-7-amine scaffold. ChemMedChem, 2017, 12, 1212–1222. https://doi.org/10.1002/cmdc.201700311

14. Sougata Dey, Louisa Temme, Julian A. Schreiber, Dirk Schepmann, Bastian Frehland, Kirstin Lehmkuhl, Nathalie Strutz-Seebohm, Guiscard Seebohm, Bernhard Wünsch. Deconstruction – reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors. Eur. J. Med. Chem., 2017, 138, 552–564. https://doi.org/10.1016/j.ejmech.2017.06.068

15. Yoshihiro Shuto, Simone Thum, Louisa Temme, Dirk Schepmann, Masato Kitamura, Bernhard Wünsch. Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain? Med. Chem. Commun., 2017, 8, 975–981. https://doi.org/10.1039/C6MD00621C

16. Andre Benner, Alessandro Bonifazi, Chikako Shirataki, Louisa Temme, Dirk Schepmann, Wilma Quaglia, Osami Shoji, Yoshihito Watanabe, Constantin Daniliuc, Bernhard Wünsch. GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: synthesis and pharmacological evaluation of benzo[7]annulen-7-amines. ChemMedChem., 2014, 9, 741–751. https://doi.org/10.1002/cmdc.201300547

Members of the working group

Julia Schick, Pharmacist, Ph.D topic: Synthesis of Eph receptor inhibitors

Jens Münchow, M.Sc Chemistry, PhD topic: Synthesis of novel CatSper modulators

Former members of the working group

Giusy Palazzolo, Erasmus M.Sc. Thesis, Chemistry and Pharmaceutical Technologies, University of Palermo, Italy.

Omar Aqlan, M.Sc. Thesis, Pharmaceutical Sciences.

Lea Flämig, M.Sc. Thesis, Chemistry.

David Eidecker, M.Sc. Thesis, Chemistry.

Jasmin Sörgel, Project module as part of M.Sc. studies, Chemistry.